IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
QULIPTA® (atogepant) is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS
Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

INDICATION

QULIPTA® (atogepant) is indicated for the preventive treatment of migraine in adults.

Please see full Prescribing Information.

*MMIT, LLC. Data as of April 2023 and subject to change.

Logo: ABBVIE

© 2023 AbbVie. All rights reserved.
US-QLP-230101  04/23